openFDA
Cure8 regulatory brief
tofacitinib FDA label update (2026-08-07)
Medications
Tofacitinib
Steroids
JAK inhibitor
Regulatory Update
Adult patients
Clinicians
Patients On Biologics
Why This Matters
This label update affects people with IBD because tofacitinib is an approved oral JAK inhibitor for moderately to severely active ulcerative colitis and the label highlights important safety risks (infections, mortality, malignancy, thrombosis) and monitoring steps that could influence treatment choice and follow-up.
Who Should Pay Attention
Adult patients with ulcerative colitis or other inflammatory conditions considering or taking tofacitinib; clinicians who prescribe JAK inhibitors; caregivers and pharmacists involved in monitoring and screening for infections and cardiovascular risk.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
This is the FDA DailyMed label update for tofacitinib extended-release tablets (a JAK inhibitor).
The label lists approved indications including moderately to severely active ulcerative colitis and other inflammatory diseases, and contains a boxed warning describing risks: serious infections (including TB and opportunistic infections), increased mortality observed in a postmarketing RA safety study versus TNF blockers, and increased risk of malignancies and thrombotic events.
The label also states combination use with biologic therapies or potent immunosuppressants (e.g., azathioprine, cyclosporine) is not recommended for UC and other indications.
The label emphasizes screening and monitoring: test for latent TB before and during therapy, monitor for signs of infection, and consider the increased risks in older patients with cardiovascular risk factors. It also notes dosage form and that certain once-daily high-dose regimens are not recommended for some indications.
This entry is a regulatory drug-label record and summarizes the safety and indication language provided by the FDA DailyMed page. It is not medical advice; patients should discuss individual risks and treatment decisions with their clinician.
Keep In Mind
This classification is based on the FDA DailyMed drug label (regulatory-record). The label summarizes approved indications, boxed warnings, and monitoring recommendations; it does not present new clinical trial results. For personalized decisions, consult a healthcare professional.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorZydus Pharmaceuticals USA Inc.
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedAug 7, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
TOFACITINIB FDA label update (2026-07-31)
This is an updated FDA drug label for tofacitinib, a JAK inhibitor that is approved for ulcerative colitis and other immune conditions.
Tofacitinib FDA label update (2026-07-27)
This DailyMed/FDA label update affects adults with moderately to severely active ulcerative colitis because it states approved use of tofacitinib extended‑release and highlights important safety warnings and recommended...
Effectiveness of tofacitinib as rescue therapy in biological-naive patients with steroid-refractory acute severe ulcerative colitis: a multicentric retrospective analysis.
This study suggests tofacitinib may work quickly as a rescue option for biologic‑naive patients with steroid‑refractory ASUC and that many achieved steroid‑free remission by 24 weeks — information that could matter when...